Source comparison
Semax Amidate for Stroke Recovery: Delivery Method Comparison
The route of administration determines whether Semax Amidate reaches the CNS at therapeutic concentrations. Peptides are notoriously poor at crossing the blood-brain barrier, and systemic delivery routes expose them to rapid enzymatic degradation. This compari
This comparison does not assign a generated winner or score.
- The route of administration determines whether Semax Amidate reaches the CNS at therapeutic concentrations. Peptides are notoriously poor at crossing the blood-brain barrier, and systemic delivery routes expose them to rapid enzymatic degradation. This comparison evaluates the three delivery methods tested in stroke models, ranked by CNS bioavailability and practical feasibility in research protocols.
- Intranasal (olfactory/trigeminal transport)
- 15–25% of administered dose reaches CNS
- 15–30 minutes
- Low. Bypasses hepatic and serum peptidases
- High. Non-invasive, repeatable dosing, no anesthesia required for chronic protocols
- Gold standard for stroke neuroprotection research. Direct nose-to-brain transport achieves therapeutic CNS levels at 1/10th the systemic dose. Consistent results across labs.
- Subcutaneous injection
- <2% CNS penetration
- 60–90 minutes
- High. Degraded by serum peptidases, limited BBB crossing
- Moderate. Simple administration but requires 5–10× higher doses to achieve equivalent CNS exposure
- Inefficient CNS delivery. Useful only for systemic ACTH-like effects. Not recommended for stroke models where CNS-specific action is required.
- Intravenous infusion
- <1% CNS penetration
- 45–60 minutes
- Very high. Immediate exposure to serum peptidases, <5 min plasma half-life
- Low. Requires vascular access, continuous infusion for sustained levels, invasive in rodent models
- Poorest CNS bioavailability. Rapid systemic clearance requires continuous dosing. Reserved for pharmacokinetic studies. Not outcome trials.
- Intranasal delivery achieves 10–15× greater CNS bioavailability than subcutaneous routes at equivalent doses because the peptide travels along olfactory nerve axons and trigeminal perineural channels directly into the subarachnoid space and olfactory bulb. This bypasses both the blood-brain barrier and hepatic first-pass metabolism. A 2019 pharmacokinetic study using radiolabeled Semax in rats found that 18% of an intranasal dose reached cortical tissue within 30 minutes, compared to 1.4% with subcutaneous injection. A 13-fold difference. For stroke research where the therapeutic window is measured in hours, the rapid onset and high CNS targeting of intranasal delivery makes it the only practical route for neuroprotection studies.